Keppra levetiracetam regulatory update

UCB submitted to FDA an sNDA for Keppra levetiracetam to treat myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (JME). UCB also submitted to EMEA a Type II var...